Valuation: Processa Pharmaceuticals, Inc.

Market Cap 83.88L 73.71L 68.8L 63.14L 1.18Cr 80Cr 1.21Cr 8.16Cr 3.19Cr 40Cr 3.15Cr 3.08Cr 137.44Cr P/E 2024
-0.23x
P/E 2025 -0.28x
Enterprise Value 28.51L 25.05L 23.38L 21.46L 40.17L 27Cr 41.16L 2.77Cr 1.08Cr 14Cr 1.07Cr 1.05Cr 47Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.1%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Processa Pharmaceuticals, Inc.

Manager TitleAgeSince
Chief Executive Officer 52 08/08/2023
Investor Relations Contact 60 29/03/2011
Chief Administrative Officer 61 04/10/2017
Director TitleAgeSince
Chairman 73 29/03/2011
Chairman 60 16/08/2022
Director/Board Member 56 13/02/2020
Change 5-day change 1-year change 3-year change Capi.($)
-38.38%-.--% - - 84.43L
+0.47%+2.03%+51.54%+70.84% 5.5TCr
+2.83%+0.04%+38.07%+82.59% 5.42TCr
+0.54%+0.67%-17.59%-13.47% 2.34TCr
-0.97%-5.06%+1.35%+383.00% 2.26TCr
+2.07%+1.44%+23.06%-9.05% 2.02TCr
-2.15%+0.78%+24.67%-31.03% 1.79TCr
-2.14%-2.72%+30.26%+536.72% 1.55TCr
-3.14%-8.09%+160.68%+292.18% 1.42TCr
-2.09%-1.41%+24.65%+178.74% 1.42TCr
Average -0.43%-1.44%+37.41%+165.61% 2.64TCr
Weighted average by Cap. +0.30%-0.75%+35.95%+130.62%

Financials

2024 2025
Net sales - -
Net income -1.19Cr -1.04Cr -97.19L -89.2L -1.67Cr -113.5Cr -1.71Cr -12Cr -4.51Cr -56Cr -4.45Cr -4.35Cr -194.17Cr -1.36Cr -1.19Cr -1.11Cr -1.02Cr -1.91Cr -129.92Cr -1.96Cr -13Cr -5.16Cr -64Cr -5.09Cr -4.98Cr -222.25Cr
Net Debt -11.18L -10L -9L -8L -15.75L -11Cr -16.14L -1.09Cr -42.52L -5.3Cr -41.97L -41.06L -18Cr -55.37L -48.65L -45.41L -41.68L -78.02L -53Cr -79.94L -5.39Cr -2.11Cr -26Cr -2.08Cr -2.03Cr -91Cr
Logo Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.
Employees
12

Quarterly revenue - Rate of surprise